National Cancer Center Hospital

Site:	National Cancer Center Hospital
Address:
City:	Chuo-ku
State:	Tokyo
Zip:	104-0045
Country:	Japan

Phase	Trial	Trial Status	Site Status [asc]	Drug	NCT#
2	Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)	Recruiting	Active, not recruiting	Belzutifan	NCT04924075
3	Phase III, Open-Label Study of Nilotinib Versus Imatinib in GIST Patients (ENESTg1)	Completed	Closed	Nilotinib or Imatinib	NCT00785785
3	Study of Regorafenib as a 3rd-line or Greater Treatment for Gastrointestinal Stromal Tumors (GIST) (GRID)	Ongoing, but not recruiting	Closed	Regorafenib (BAY 73-4506)	NCT01271712
1	Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer	Ongoing, but not recruiting	Closed	Cabozantinib	NCT01553656